| Patents for C12P 21 - Preparation of peptides or proteins (112,499) |
|---|
| 07/05/2000 | EP0794958A4 Pcr amplification of rearranged genomic variable regions of immunoglobulin genes |
| 07/05/2000 | EP0619839B1 Novel polypeptides for promoting cell attachment |
| 07/05/2000 | EP0577752B1 Human pf4a receptors and their use |
| 07/05/2000 | CN1258750A Preparation of protein oligopeptide |
| 07/04/2000 | US6084084 Nucleotide and amino acid sequences; for anticonvulsants, neuroprotectants, analgesics and cognition enhancers; for diagnosis and therapy of related nervous system disorders |
| 07/04/2000 | US6084076 Method of refolding human activin A |
| 07/04/2000 | US6084075 Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2) |
| 07/04/2000 | US6083904 Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
| 07/04/2000 | US6083902 Recombinant fibrin chains, fibrin and fibrin-homologs |
| 07/04/2000 | US6083749 DNA encoding a human serotonin receptor (5-HT4B) and uses thereof |
| 07/04/2000 | US6083748 Antibodies which specifically bind to a novel κ/μ-like protein tyrosineospatase, PTPλ, and hybridoma cell lines producing the same |
| 07/04/2000 | US6083746 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells |
| 07/04/2000 | US6083745 Genes and genetic elements associated with control of neoplastic transformation in mammalian cells |
| 07/04/2000 | US6083743 Dna and amino acid sequences; for diagnosis and treatment of infections including otitis media, epiglottitis, pneumonia, and tracheobronchitis; for immunogenic compositions/vaccines |
| 07/04/2000 | US6083735 Programmed cell death genes and proteins |
| 07/04/2000 | US6083725 Nucleotide sequences coding a mammalian enzymatic polypeptide; for gene therapy of lysosomal storage defect |
| 07/04/2000 | US6083722 Borrelia antigen |
| 07/04/2000 | US6083720 Dodecahedral adenoviral protein complex, composition containing same and uses thereof |
| 07/04/2000 | US6083715 Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| 07/04/2000 | US6083713 Nucleotide sequences coding binding polypeptide for the terminal domain of the amyloid precursor protein; for the diagnosis and design of drugs for treatment of alzheimer's disease |
| 07/04/2000 | US6083712 Biotechnological method of producing biotin |
| 07/04/2000 | US6083705 Screening for chemical compound which preferentially binds to binding protein; incubation of compound with cells expressing binding protein, detecting preferential binding of compound to surface of cell not normally expressing binding protein |
| 07/04/2000 | US6083693 Identification and comparison of protein-protein interactions that occur in populations |
| 07/04/2000 | US6083511 Isolated equine herpesvirus-4 (ehv-4) or gh or gc polypeptides and antigenic fragments; vaccine for the protection of horses against ehv-4 infection |
| 07/04/2000 | US6083478 Consists of a cytotoxic radionuclide and a homodimer comprising two heavy chains encoded by the expression vector designated cd4-igg2-pcdna1 (atcc no. 40952) |
| 07/04/2000 | CA2082799C Process for preparing peptides |
| 07/04/2000 | CA1341042C Y, & t cell receptor and methods for detection |
| 06/29/2000 | WO2000037642A1 Method of enhancing the biological activity of ligands |
| 06/29/2000 | WO2000037640A2 Compositions and methods for the treatment of tumor |
| 06/29/2000 | WO2000037639A2 Lymphocytic membrane proteins |
| 06/29/2000 | WO2000037638A2 Methods and compositions for inhibiting neoplastic cell growth |
| 06/29/2000 | WO2000037637A1 Novel protein and dna thereof |
| 06/29/2000 | WO2000037632A1 Monoclonal antibody against apolipoprotein a-i |
| 06/29/2000 | WO2000037615A1 Recombinant synthesis of beta-lipotropin and other peptides |
| 06/29/2000 | WO2000037613A2 Human akt-3 |
| 06/29/2000 | WO2000037612A1 SOMATIC CELLS WITH ABLATED Prp GENE AND METHODS OF USE |
| 06/29/2000 | WO2000037504A2 Human monoclonal antibodies to ctla-4 |
| 06/29/2000 | WO2000037503A1 Compositions and methods for generating monoclonal antibodies representative of a specific cell type |
| 06/29/2000 | WO2000037494A2 Chlamydia trachomatis antigens |
| 06/29/2000 | WO2000037493A2 Type iii secretion system antigens from bordetella pertussis |
| 06/29/2000 | WO2000037491A2 Dnas encoding proteins with signal sequences |
| 06/29/2000 | WO2000037489A2 Fragment of the gylcoprotein cd55/daf for producing highly effective anti-tumour medicaments and method for using the same |
| 06/29/2000 | WO2000037483A1 Protein-protein interactions in neurodegenerative disorders |
| 06/29/2000 | WO2000037104A1 Improved recombinant hepatitis b surface antigen |
| 06/29/2000 | WO2000037102A2 Improvement of tolerance to a xenograft |
| 06/29/2000 | WO2000037093A1 Bone resorption inhibitors |
| 06/29/2000 | WO2000037025A2 Antibodies to truncated vegf-d and uses thereof |
| 06/29/2000 | WO2000036920A1 Polynucleotide and polypeptide sequences of rabbit g-protein alpha 16 |
| 06/29/2000 | WO2000008180A3 HUMAN cDNAs ENCODING POLYPEPTIDES HAVING KINASE FUNCTIONS |
| 06/29/2000 | WO2000006737A3 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 06/29/2000 | WO2000006717A3 Improved transformation efficiency in phage display through modification of a coat protein |
| 06/29/2000 | WO2000006605A3 Heterominibodies |
| 06/29/2000 | WO2000004861A8 Agents that bind to and inhibit human cytochrome p450 2a6 |
| 06/29/2000 | WO2000001817A3 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods |
| 06/29/2000 | WO2000000610A3 Human signal peptide-containing proteins |
| 06/29/2000 | WO1999067415A9 Novel molecules of the t110-related protein family and uses thereof |
| 06/29/2000 | WO1999049019A3 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 06/29/2000 | DE19909771A1 Substanz zur Gewinnung hochwirksamer Tumorarzneien sowie Verfahren Substance for the production of highly effective tumor drugs and methods |
| 06/29/2000 | CA2450402A1 Methods and compositions for inhibiting cancer cell growth comprising pro224 |
| 06/29/2000 | CA2358086A1 Protein-protein interactions in neurodegenerative disorders |
| 06/29/2000 | CA2356765A1 Bone resorption inhibitors |
| 06/29/2000 | CA2356764A1 Type iii secretion system antigens from bordetella pertussis |
| 06/29/2000 | CA2356738A1 Monoclonal antibody against apolipoprotein a-1 |
| 06/29/2000 | CA2356244A1 Somatic cells with ablated prp gene and methods of use |
| 06/29/2000 | CA2356215A1 Human monoclonal antibodies to ctla-4 |
| 06/29/2000 | CA2355968A1 Novel protein and dna thereof |
| 06/29/2000 | CA2355896A1 Antibodies to truncated vegf-d and uses thereof |
| 06/29/2000 | CA2355876A1 Chlamydia trachomatis antigens |
| 06/29/2000 | CA2355680A1 Improved recombinant hepatitis b surface antigen |
| 06/29/2000 | CA2355402A1 Recombinant synthesis of beta-lipotropin and other peptides |
| 06/29/2000 | CA2355074A1 Lymphocytic membrane proteins |
| 06/29/2000 | CA2354846A1 Method of enhancing the biological activity of ligands |
| 06/29/2000 | CA2354369A1 Complementary dna's encoding proteins with signal peptides |
| 06/29/2000 | CA2353960A1 Improvement of tolerance to a xenograft |
| 06/29/2000 | CA2353799A1 Methods and compositions for inhibiting neoplastic cell growth |
| 06/29/2000 | CA2353775A1 Compositions and methods for the treatment of tumor |
| 06/29/2000 | CA2352471A1 Compositions and methods for generating monoclonal antibodies representative of a specific cell type |
| 06/28/2000 | EP1013771A1 Non-nuclear chromosomal transformation |
| 06/28/2000 | EP1013766A2 Peptides for the detection of HIV-1-Group O |
| 06/28/2000 | EP1013764A1 Immunomodulators |
| 06/28/2000 | EP1013762A2 Delta-like gene expressed in neuroendocrine tumors |
| 06/28/2000 | EP1013761A2 Humanized chimeric antibody directed against ganglioside GD3 |
| 06/28/2000 | EP1013760A2 Stable bactericidal/permeabilityincreasing protein products and pharmaceutical compositions containing the same |
| 06/28/2000 | EP1013668A1 Monoclonal antibody against human monocytes |
| 06/28/2000 | EP1013666A2 Methods for obtaining a p53/p90 complex |
| 06/28/2000 | EP1013665A1 Novel polypeptide having water channel activity and dna sequence |
| 06/28/2000 | EP1013285A2 Urokinase-type plasminogen activator receptor |
| 06/28/2000 | EP1012347A1 Determination and control of bimolecular interactions |
| 06/28/2000 | EP1012333A1 ISOLATION OF A NOVEL SENESCENCE-FACTOR GENE, p23 |
| 06/28/2000 | EP1012320A2 Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses |
| 06/28/2000 | EP1012319A2 Insect expression vectors |
| 06/28/2000 | EP1012311A1 G protein chimeras |
| 06/28/2000 | EP1012307A1 Zymogenic protease precursors that can be autocatalytically activated and their use |
| 06/28/2000 | EP1012306A2 Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
| 06/28/2000 | EP1012303A1 Factor x deletion mutants and analogues thereof |
| 06/28/2000 | EP1012296A2 Mammalian thioredoxin |
| 06/28/2000 | EP1012292A1 Ntn-2 member of tnf ligand family |
| 06/28/2000 | EP1012290A1 EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM) |
| 06/28/2000 | EP1012289A1 A recombinant expression vector of human parathyroid hormone using phosphoribulokinase as a fusion partner |
| 06/28/2000 | EP1012288A1 Novel human cystatin-like protein |